Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis

PURPOSE: To explore the risk of stroke (including ischemic and hemorrhagic stroke) in type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP-1RA) medication according to data from the Cardiovascular Outcome Trials(CVOT). METHODS: Randomized controlled trials (RCT) on GLP...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jinjing, Yang, Bing, Wang, Ruxin, Ye, Haowen, Wang, Ying, Wang, Lihong, Zhang, Xiaofang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760859/
https://www.ncbi.nlm.nih.gov/pubmed/36545339
http://dx.doi.org/10.3389/fendo.2022.1007980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760859/
https://www.ncbi.nlm.nih.gov/pubmed/36545339
http://dx.doi.org/10.3389/fendo.2022.1007980

Ejemplares similares